Top

Published in:

01-11-2009 | CLINICAL TRIAL UPDATES AND HOTLINE SESSIONS

Hotlines and clinical trial updates presented at the European Society of Cardiology Meeting 2009: data from RE-LY, PLATO, MADIT-CRT, PROTECT, SYNTAX, TRITON and more

Authors: S. H. Schirmer, A. M. van der Laan, M. Böhm, F. Mahfoud

Published in: Clinical Research in Cardiology | Issue 11/2009

Abstract

This summary article provides an update on novel clinical trials in the field of cardiovascular (CV) medicine which were presented at the annual meeting of the European Cardiac Society, held in Barcelona, Spain, in August–September 2009. The data were presented by leading experts in the field with relevant positions in the trials and registries. Unpublished reports should be considered as preliminary data as the analysis may change in the final publications. This article provides the reader with comprehensive summaries of the most recent diagnostic and therapeutic developments in CV medicine as previously reported (Kindermann et al. in Clin Res Cardiol 96:767–786, 2007; Müller et al. in Clin Res Cardiol 97:851–864, 2008).

Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373:1849–1860CrossRefPubMed

Böhm M, Thoenes M, Neuberger HR, Graber S, Reil JC, Bramlage P, Volpe M (2009) Atrial fibrillation and heart rate independently correlate to microalbuminuria in hypertensive patients. Eur Heart J 30:1364–1371CrossRefPubMed

Bohmer E, Hoffmann P, Abdelnoor M, Amesen H, Halvorsen S (2009) Efficacy and safety of immediate angioplasty versus ischemia-guided management after thrombolysis in acute myocardial infarction in areas with very long transfers. J Am Coll Cardiol. doi:10.1016/j.jacc.2009.08.007

Byrne RA, Kastrati A, Kufner S, Massberg S, Birkmeier KA, Laugwitz K-L, Schulz S, Pache J, Fusaro M, Seyfarth M, Schomig A, Mehilli J, for the Intracoronary S, Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents I (2009) Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. Eur Heart J. doi:10.1093/eurheartj/ehp352

Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Yusuf S (2006) Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367:1903–1912CrossRefPubMed

Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener H-C, Joyner CD, Wallentin L, the RELYSC, Investigators (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151

Di Mario C, Dudek D, Piscione F, Mielecki W, Savonitto S, Murena E, Dimopoulos K, Manari A, Gaspardone A, Ochala A, Zmudka K, Bolognese L, Steg PG, Flather M (2008) Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial. Lancet 371:559–568CrossRefPubMed

Fernandez-Aviles F, Alonso JJ, Castro-Beiras A, Vazquez N, Blanco J, Alonso-Briales J, Lopez-Mesa J, Fernandez-Vazquez F, Calvo I, Martinez-Elbal L, San Roman JA, Ramos B (2004) Routine invasive strategy within 24 hours of thrombolysis versus ischaemia-guided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA-1): a randomised controlled trial. Lancet 364:1045–1053CrossRefPubMed

Fox K, Ford I, Steg PG, Tendera M, Ferrari R (2008) Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 372:807–816CrossRefPubMed

10.

Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R, on behalf of the Bi (2009) Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J. doi:10.1093/eurheartj/ehp358

11.

Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, Rumsfeld JS (2009) Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 301:937–944CrossRefPubMed

12.

Jondeau G, Neuder Y, Eicher J-C, Jourdain P, Fauveau E, Galinier M, Jegou A, Bauer F, Trochu JN, Bouzamondo A, Tanguy M-L, Lechat P, for the BCI (2009) B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode. Eur Heart J 30:2186–2192

13.

Kindermann M, Adam O, Werner N, Böhm M (2007) Clinical trial updates and hotline sessions presented at the European Society of Cardiology Congress 2007: (FINESSE, CARESS, OASIS 5, PRAGUE-8, OPTIMIST, GRACE, STEEPLE, SCAAR, STRATEGY, DANAMI-2, ExTRACT-TIMI-25, ISAR-REACT 2, ACUITY, ALOFT, 3CPO, PROSPECT, EVEREST, COACH, BENEFiT, MERLIN-TIMI 36, SEARCH-MI, ADVANCE, WENBIT, EUROASPIRE I-III, ARISE, getABI, RIO). Clin Res Cardiol 96:767–786CrossRefPubMed

14.

Maggioni AP, Fabbri G, Lucci D, Marchioli R, Franzosi MG, Latini R, Nicolosi GL, Porcu M, Cosmi F, Stefanelli S, Tognoni G, Tavazzi L, on behalf of the G-HFI (2009) Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. Eur Heart J. doi:10.1093/eurheartj/ehp357

15.

Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA (2001) Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358:527–533CrossRefPubMed

16.

Mollmann H, Nef H, Böhm M, Laufs U (2009) Highlights of the hotline sessions presented at the scientific sessions 2008 of the American Heart Association. Clin Res Cardiol 98:1–7CrossRefPubMed

17.

Montalescot G, Brieger D, Eagle KA, Anderson FA Jr, FitzGerald G, Lee MS, Steg PG, Avezum A, Goodman SG, Gore JM, for the GI (2009) Unprotected left main revascularization in patients with acute coronary syndromes. Eur Heart J. doi:10.1093/eurheartj/ehp353

18.

Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, Antman EM (2009) Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 373:723–731CrossRefPubMed

19.

Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes NAM III, Foster E, Greenberg H, Higgins SL, Pfeffer MA, Solomon SD, Wilber D, Zareba W, the M-CRTTI (2009) Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. doi:10.1056/NEJMoa0906431

20.

Müller P, Rosenkranz S, Adam O, Custodis F, Böhm M (2008) Clinical trial updates and hotline sessions presented at the European Society of Cardiology Congress 2008. Clin Res Cardiol 97:851–864CrossRefPubMed

21.

O’Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, Michelson AD, Hautvast RW, Ver Lee PN, Close SL, Shen L, Mega JL, Sabatine MS, Wiviott SD (2009) Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet

22.

Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM Jr, Kastelein JJP, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, the JSG (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359:2195–2207CrossRefPubMed

23.

Sabatine MS, Antman EM, Widimsky P, Ebrahim IO, Kiss RG, Saaiman A, Polasek R, Contant CF, McCabe CH, Braunwald E (2009) Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial. Lancet 374(9692):787–795CrossRefPubMed

24.

Schillinger W, Hornes N, Teucher N, Sossalla S, Sehrt D, Jung K, Hunlich M, Unsold B, Geiling B, Ramadori G, Hilgers R, Schworer H, Hasenfuss G (2009) Recent in vitro findings of negative inotropy of pantoprazole did not translate into clinically relevant effects on left ventricular function in healthy volunteers. Clin Res Cardiol 98:391–399CrossRefPubMed

25.

Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, Stahle E, Feldman TE, van den Brand M, Bass EJ, Van Dyck N, Leadley K, Dawkins KD, Mohr FW (2009) Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 360:961–972CrossRefPubMed

26.

Smilde TD, Damman K, van der Harst P, Navis G, Daan Westenbrink B, Voors AA, Boomsma F, van Veldhuisen DJ, Hillege HL (2009) Differential associations between renal function and “modifiable” risk factors in patients with chronic heart failure. Clin Res Cardiol 98:121–129CrossRefPubMed

27.

Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G (2008) Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372:1231–1239CrossRefPubMed

28.

Voss F, Becker R, Hauck M, Katus HA, Bauer A (2009) The basic pacing rate in CRT patients: the higher the better? Clin Res Cardiol 98:219–223CrossRefPubMed

29.

Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, the PI (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045–1057

Title: Hotlines and clinical trial updates presented at the European Society of Cardiology Meeting 2009: data from RE-LY, PLATO, MADIT-CRT, PROTECT, SYNTAX, TRITON and more
Authors: S. H. Schirmer
A. M. van der Laan
M. Böhm
F. Mahfoud
Publication date: 01-11-2009
Publisher: D. Steinkopff-Verlag
Published in: Clinical Research in Cardiology / Issue 11/2009
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI: https://doi.org/10.1007/s00392-009-0085-2

2024 ASCO Annual Meeting

Springer Medicine

Hotlines and clinical trial updates presented at the European Society of Cardiology Meeting 2009: data from RE-LY, PLATO, MADIT-CRT, PROTECT, SYNTAX, TRITON and more

Abstract

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2009

Short-term prognosis of contemporary interventional therapy of ST-elevation myocardial infarction: does gender matter?

Cobalt–chrome MULTI-LINK VISION™-stent implantation in diabetics and complex lesions: results from the DaVinci-Registry

Fractal scaling properties of heart rate dynamics and myocardial efficiency in dilated cardiomyopathy

Pulmonary arteriovenous fistula in hereditary hemorrhagic telangiectasis

Adenosine-induced maximal coronary hyperemia for myocardial fractional flow reserve measurements: comparison of administration by femoral venous versus antecubital venous access

In-hospital outcomes after elective and non-elective percutaneous coronary interventions in hospitals with and without on-site cardiac surgery backup